OrganOx signs research collaboration agreement with two leading US transplant organizations

British MedTech business, OrganOx Ltd, announced today a multiyear research collaboration with two leading US organ transplant organizations, with the objective of increasing the supply of donor livers available for transplantation within the US. 

 

Currently, approximately 15%* of donor livers recovered in the US are not transplanted, primarily due to concerns over organ quality. Evidence from the UK, using the OrganOx technology, has suggested that many of these ~1,000 declined organs may be viable for transplantation. 

 

Mid-America Transplant and Washington University School of Medicine, both based in St. Louis, will collaborate with OrganOx to evaluate whether the company’s metra** normothermic machine perfusion (NMP) device can reduce the number of livers that are discarded due to quality issues. The machine is designed to supply donated livers with oxygenated blood, clot-busting drugs and nutrients. Currently, donated livers are stored on ice, making them prone to a type of injury that occurs when blood flows through the organ for the first time after a transplant. 

 

Diane Brockmeier, CEO of Mid-America Transplant, said “We take pride in innovating the donation process by seeking out new, novel approaches that align with the pursuit of our vision that organs and tissues are always available to those in need. We are delighted to work with OrganOx and Washington University to assess the impact NMP can make in our commitment to save lives through organ and tissue donation.” 

 

William Chapman MD, Chief of Transplant Surgery at Washington University, said “Today the shortage of donor organs remains the overriding factor that limits our ability to save the lives of patients with end-stage liver disease for whom a transplant is the only treatment. Our long-term vision is to expand the supply of suitable donor organs in the US and increase the number of patients who are eligible for a transplant. We look forward to evaluating the NMP technology to determine whether it will facilitate the ability to assess livers that would otherwise be discarded.” 

 

Craig Marshall, CEO of OrganOx said, “We are delighted to announce this collaboration with Mid-America Transplant and Washington University, St Louis. Improving the utilization of donor organs is exactly what our proprietary technology has been developed for. I am confident OrganOx can play a crucial role in enabling Diane Brockmeier’s and Dr. Chapman’s shared vision of expanding the number of donor livers available for transplant to enable more recipients to benefit from lifesaving transplantation. This is great news for the growing number of US patients with end stage liver disease.”  

About the OrganOx technology 

The technology, normothermic machine perfusion, (NMP) has been developed by OrganOx, a company spun out of the University of Oxford, UK. It is a totally new approach to preserving a deceased donor liver prior to transplantation. Instead of storing the donor liver in ice, NMP provides the organ with oxygenated blood and nutrients at normal body temperature which allows it to function in the critical period between the donation and transplantation and enables an assessment of the organ prior to transplant. 

About liver transplantation in the US 

Today the US leads the world in terms of the number of liver transplants performed each year at approximately 8,000, however the demand is far greater, with more than 13,000 patients joining the transplant list annually. By contrast over 1,000 donor organs are recovered but not transplanted each year, primarily due to concerns over organ quality. In the absence of an equivalent to dialysis, more than 10 people a day die or are removed from the list whilst waiting for a liver transplant*. 

Within the US the recovery of donor organs is the responsibility of the network of 58 Organ Procurement Organizations (OPOs), which work with donor families and operate on a not for profit basis. Liver transplantation takes place in 145 hospitals, each one affiliated to one or more OPO. 

About Mid-America Transplant 

Mid-America Transplant is a leading OPO in the US headed by CEO, Diane Brockmeier. The organization saves lives by providing expert and compassionate care for donors, donor families, and recipients, and transforms the clinical processes required to recover and transplant organs and tissues. Mid-America was the first OPO to establish an independent organ recovery facility in which organs are retrieved and transferred to surrounding transplant hospitals. 

About Washington University, St Louis 

The Washington University liver transplant program has performed more than 2,000 liver transplants and is headed by William Chapman, MD. With a reputation for leading-edge research and exceptional clinical care, the transplant center was the 4th largest in the United States in 2017, and is a leader in both transplant numbers and clinical outcomes. 

For further information, please contact Joanna Bright, Email: joanna@joannabright.co.uk Tel: + 44 (0) 7768 646430 

*Source: OPTN 

** The OrganOx metra is not currently available in the United States. Discarded liver studies using the OrganOx metra are for Research Use Only purposes at this time.

Chapman_MidAmericaTransplant.jpg

NICE: "More donor livers could be used for transplantation thanks to exciting new development"

OrganOx, the UK innovator behind normothermic machine perfusion (NMP), welcomes the NICE assessment of machine perfusion released today which highlights the technology as an ‘exciting development in increasing the number of livers which can be safely used for transplantation’.

Whereas the traditional method of organ preservation requires cooling and storage in an ice box, NMP with the OrganOx metra device maintains the liver at normal body temperature prior to transplantation and actively delivers oxygenated blood, medications and nutrients. This greatly reduces the tissue injury associated with transplantation and enables quality assessment of the donor liver prior to transplantation.

In 2017, over 500 livers from deceased organ donors in the UK were either not retrieved or retrieved but not transplanted. In many cases this was because the condition of the donor organ was such that they were unlikely to function after being preserved in an ice box.

Professor Chris Watson, Professor of Transplantation, University of Cambridge, commented “In the past year we have used the OrganOx technology more than 30 times and increased the number of liver transplants we perform by around 20%. With this technology we are able to make an informed decision about the viability of a donor liver based on its function, not merely on its appearance. The impact of this technology nationally is that many more patients will receive a transplant, which is great news for patients waiting on the transplant list”.

Read the NICE article here: https://www.nice.org.uk/news/article/more-donor-livers-could-be-used-for-transplantation-thanks-to-exciting-new-development-nice-says

Breakthrough warm transplant technology deployed in India for the first time

OrganOx and its exclusive business partner in India, Duraent Biologicals Ltd are delighted to announce the first liver transplant in India using a new breakthrough technology.

The technology, normothermic machine perfusion(NMP), was developed by OrganOx and is a totally new approach to preserving a deceased donor liver prior to transplantation. Instead of storing the donor liver on ice, NMP maintains the liver at physiological temperature and provides the organ with oxygenated blood and nutrients. This enables quality assessment of the organ by functional testing prior to transplant

This first transplant in India took place on 9th April 2018, at the Aster CMI Hospital in Bengaluru. In attendance were the hospital’s lead transplant surgeon Dr. Sonal Asthana accompanied by Professor Darius Mirza and Professor Arvinder Soin who were present in their capacity as OrganOx consultant advisors.

The 56-year-old male patient has made a very good recovery and has been discharged from the Aster CMI Hospital.

This development comes shortly after results from the world’s first randomized clinical trial of NMP with the OrganOx metra® were published on-line by the science journal Nature on 18th April 2018.

The results show livers preserved using the metra device had improved outcomes and increased utilisation compared to ice stored organs.

To read the Nature study visit https://www.nature.com/articles/s41586-018-0047-9 or to read the article visit https://www.nature.com/articles/d41586-018-04816-8

download.jpg

Breakthrough technology points to a new era for liver transplantation

OrganOx is delighted to announce the publication of a multinational clinical trial  ('A randomized trial of normothermic preservation in liver transplantation') in Nature, the international journal of science.

In the first randomized study of its kind, transplanted livers were shown to function better if they had been preserved using the OrganOx metra device. This benefit was most pronounced in the most ‘marginal’ donor livers.   Preservation using the metra device was also associated with increased use of available donor organs.

Funded by the European Commission, 220 livers were transplanted in this randomized controlled study across seven European transplant centres. Conventional organ preservation, in an ice box, (static cold storage (SCS)) was compared with storage using the metra device.

Whereas the traditional method of organ preservation requires cooling and storage in an ice box, normothermic machine perfusion with the OrganOx metra device maintains the liver at normal body temperature prior to transplantation and actively delivers oxygenated blood, medications and nutrients. This greatly reduces the tissue injury associated with transplantation and enables quality assessment by functional testing of the organ.

“We are in the business of saving lives by saving donor organs” said Craig Marshall, CEO of OrganOx Ltd. “By changing the way the donor livers are preserved and evaluated before they are transplanted, we expect to see more donor livers being transplanted. Our company is at the forefront of this exciting new technology, and we are also researching other applications for our platform to help address liver disease – which is predicted to become the largest cause of premature deaths by 2020.”    

To read the study visit https://www.nature.com/articles/s41586-018-0047-9 or to read the article visit https://www.nature.com/articles/d41586-018-04816-8

 

OrganOx_metra_Setup.jpg

Pioneering Clinical Trial Featured by BBC

The OrganOx metra device was recently featured in use for a pioneering clinical trial (VITTAL) by the liver transplant team at the Queen Elizabeth II Hospital, Birmingham, UK. This pioneering study team is placing livers declined for transplant by all UK liver transplant centres on the OrganOx metra device, assessing their quality, and if deemed viable, transplanting them.  Watch the documentary on BBC iPlayer (only available within the UK) HERE

BBC image .jpg